FDA-TRACK: Center for Drug Evaluation & Research - Post-Approval Safety Monitoring - Drug Shortages Dashboard
Policy and Science
Development
Pre-Approval Safety
Review
Post-Approval Safety
Monitoring
Relevant Links:
FDA’s Center for Drug Evaluation and Research (CDER) regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. CDER also regulates other non-medicines that are considered to be drugs like fluoride toothpaste, antiperspirants, dandruff shampoos and sunscreens. CDER protects and advances public health by ensuring safe and effective drugs are available to improve the health of people in the United States.
FDA takes great efforts, within its legal authority, to address and prevent drug shortages, which can occur for many reasons, including manufacturing and quality problems, delays, and discontinuations. FDA responds to potential drug shortages by taking actions to address their underlying causes and to enhance product availability. FDA determines how best to address each shortage situation based on its cause and the public health risk associated with the shortage by working with firms to address any potential risks to keep medically necessary products available while also ensuring there is not going to be harm to patients associated with the quality issues.
Download Drug Shortages Dataset PDF / Print Version
Footnotes:
- Drug shortage data is available on an annual basis. Data will be posted once finalized, typically in April for the previous Calendar Year.
- The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. The data presented in the visualizations above can be accessed by clicking on the link labeled "Download Drug Shortages Dataset" located right below the visualizations.